Announcements Trials

Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Stomach Neoplasms 7 Esophageal Neoplasms 4 Gastrointestinal Neoplasms 3 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Adenocarcinoma 2 Solid Tumor 1 Rectal Neoplasms 1 Patients With Advanced or Metastatic Solid Tumors 1 Pathologic Complete Response 1 Neoplasms, Unknown Primary 1 Nasopharyngeal Carcinoma 1 Locally Advanced Gastric Adenocarcinoma 1 Hand-Foot Syndrome 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 14 Injections 13 Paclitaxel 10 Nivolumab 10 Docetaxel 9 Cisplatin 9 Capecitabine 9 Bevacizumab 8 toripalimab 7 senaparib 7 Fluorodeoxyglucose F18 7 Cyclophosphamide 7 tislelizumab 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 Gemcitabine 5 fludarabine 4 apatinib 4 Oxaliplatin 4 Leucovorin 4 Ipilimumab 4 Carboplatin 4 spartalizumab 3 sintilimab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × tegafur-gimeracil-oteracil × Clear all

NCT04260269 2024-12-12

CardioSwitch

Helsinki University Central Hospital

Enrolling by invitation

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡